Research Expert: Sarah Overall
  • Published: Jun 2025
  • Pages: 150
  • SKU: IRTNTR72448

  • Latest News- Liver Cancer Drugs Market: Immunotherapy is expected to lead the Type segment during 2025-2029

    The Liver Cancer Drugs Market is being driven by Increasing incidence of liver cancer

    The Liver Cancer Drugs Market is expected to grow at a CAGR of 10.7% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 3869.5 million. Monoclonal antibodies represent a promising approach in the liver cancer drug market due to their high specificity and sensitivity towards tumor-specific antigens. The primary challenge in developing effective liver cancer treatments lies in identifying tumor-specific targets. To address this, research is focused on creating high-stability and high-affinity antibodies and fragments that can target these antigens. Monoclonal antibodies offer several advantages, including reduced side effects due to their specificity and high stability. Success in this field relies on the appropriate selection of high-affinity antibodies through library screening, identification of proteomic biomarkers, and optimization of clinical feasibility through engineering aimed at decreased antigenicity and decreased renal clearance rates. 

    Get more information on Liver Cancer Drugs Market by requesting a sample report

    Which Factors Are Causing a Surge in Market Growth?

    The market is segmented based on

    • Type
      • Immunotherapy
      • Targeted therapy
    • Drug Class
      • Targeted therapy drugs
      • Immunotherapy drugs
      • Chemotherapeutics
      • Others
    • Route Of Administration
      • Oral
      • Injectable
      • Others
    • Distribution Channel
      • Hospital pharmacies
      • Retail pharmacies
      • Online pharmacies
      • Others
    • Geography
      • North America
        • Mexico
        • US
      • Europe
        • Germany
        • UK
        • France
        • Italy
        • Spain
      • Asia
        • China
        • India
        • Japan
        • South Korea
      • Rest of World (ROW)

      According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

      • Increasing incidence of liver cancer
      • Advancements in diagnostic methods
      • Favorable reimbursement scenario

      However, the market also witnesses some limitations, which are as follows:

      • Only curative option is surgical resection and transplantation
      • High rate of drug resistance and underlying liver dysfunction
      • Low prognosis

      Benefits of Buying Global Liver Cancer Drugs Market Research Report by Technavio

      Rich Experience: 20+ years leading global market research, trusted insights across industries.

      Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

      Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

      Market Scope in Liver Cancer Drugs Market Research Report

      Market Scope

      Report Coverage

      Details

      Page number

      236

      Base year

      2024

      Historic period

      2019-2023

      Forecast period

      2025-2029

      Growth momentum & CAGR

      Accelerate at a CAGR of 10.7%

      Market growth 2025-2029

      USD 3869.5 million

      Market structure

      fragmentation

      YoY growth 2024-2025(%)

      9.4

      Key countries

      US, China, Germany, Japan, UK, Australia, India, France, Brazil, UAE, Rest of World (ROW), Saudi Arabia, France, South Korea, Mexico, Italy, Spain, US, Germany, Canada, China, Japan, UK, France, India, Italy, and South Korea

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Find out which segment is leading the market by accessing the free PDF report

      Research Analysis Overview

      The Liver Cancer Drugs Market encompasses innovative treatments such as PD-1 inhibitors, surgical resection, liver transplantation, stem cell therapy, and gene therapy. Clinical practice guidelines, healthcare providers, and patient advocacy groups influence market trends. The payer landscape, healthcare policy, and regulatory landscape shape market access. Intellectual property, clinical data management, data analytics, artificial intelligence, machine learning, and predictive modeling are essential for drug development and treatment decision support.

      Market Research Overview

      In the dynamic landscape of the global pharmaceuticals market, targeted therapies, including molecularly targeted agents, monoclonal antibodies, and kinase inhibitors, play a pivotal role in the treatment of liver cancer. These innovative drugs are designed to specifically target cancer cells, minimizing damage to healthy cells. The market encompasses entities involved in research and development (R&D) or production of various pharmaceutical offerings, including generic and non-generic drugs, as well as veterinary drugs. According to Technavio's market analysis, the growth of this sector will be fueled by demographic trends, such as an aging population. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to surpass 60 years old, increasing the demand for healthcare solutions, including liver cancer drugs.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.


      Contacts

      Technavio Research
      Jesse Maida
      Media & Marketing Executive
      US: +1 844 364 1100
      UK: +44 203 893 3200
      Email: media@technavio.com
      Website: www.technavio.com/

      Read News Read Less
      Interested in this report?
      Get your sample now!

    Safe and Secure SSL Encrypted

    Technavio

    • 2500 USD

    [5 reports/month/user]

    • 5000 USD

    close
    • Basic Plan [5000 USD/Year]:

      Single User
      Download 5 Reports/Month
      View 100 Reports/Month
      Add upto 3 Users at 625 USD/user

    • Teams Plan [7500 USD/Year]:

      5 User
      Download 5 Reports/Month/User
      View 100 Reports/Month/User
      Add upto 30 Users at 500 USD/user

    *You can upgrade to Teams plan at Subscription page

    close
    • Single:

      One user only.
      Quick & easy download option

    • Enterprise:

      Unlimited user access (Within your organization).
      Complimentary Customization Included

    *For Enterprise license, go to checkout page

    Technavio Get the report (PDF) sent to your email within minutes.